Zika virus is currently present in over 90 countries and spreading at a rapid pace, thanks to Aedes aegypti mosquitoes, which ...

BENGALURU: Vaccines and antiviral, although not very effective are there for flu virus, however there are none which are clinically approved for mosquito borne ...

Bhopal: AIIMS Bhopal department of microbiology has secured NABL accreditation. The department stands out for having two NABL ...

Guillain-Barre Syndrome (GBS) is a serious illness that often progresses rapidly, making the patient bedridden in a few days ...

Cases of Chikungunya among children are being reported in recent days, Lady Ridgeway Hospital’s Consultant Paediatrician Dr. Deepal Perera said.Dr. Perera highlighted that the disease is spread by ...

When you think about infectionsclassically the thought runs to malariawith recent cases also in Italy, tuberculosis or HIV ...

Valneva’s growth potential lies in Ixchiq, but risks remain. Find out why VALN stock is still a Buy with a good long-term ...

Valneva’s vaccine was highly immunogenic in both dose groups. A full dose of the vaccine exhibited a more robust immune response compared to a half dose by providing protective antibody titers already ...

Valneva chikungunya vaccine shows strong, sustained immune response in adolescents, supporting potential approvals in Brazil and other regions.

The FDA is reviewing new vaccines for meningitis and chikungunya and therapies for Parkinson disease and PTSD.

Valneva (VALN) stock rose after the company posted new Phase 3 trial data for its chikungunya vaccine, Ixchiq, in adolescents aged 12-17. Read more here.

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported further positive Phase 3 data in adolescents for its single-shot chikungunya virus (CHIKV) vaccine, IXCHIQ ® ...